A Phase 3 interventional study of terbinafine hydrogen chloride and amorolfine nail lacquer in Onychomycosis, sponsored by Novartis. Completed at 10 sites in 10 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-05-06.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing terbinafine in Onychomycosis — 1 open to participants now, 2 under way, 1 of them phase 3. Terbinafine · Onychomycosis.
Among the 20 studies testing terbinafine in Onychomycosis, this one has the largest enrollment of the 19 interventional ones that give a count, is the only one that started in 2007, is one of 10 in phase 3, and was the 3rd registered.
158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.
Browse Onychomycosis studies →1 of the 20 studies testing terbinafine in Onychomycosis is open now. Recruiting first, the newest first:
Terbinafine: first FDA approval 1992 (LAMISIL). What it is approved for, and how studies give it, is on its page →
Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,029 is above the median of 60 across 143 interventional studies indexed under Onychomycosis.
Median enrollment 100 across the 19 interventional studies. Of the 14 that completed or were terminated, 3 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Novartis has 3 studies filed under Onychomycosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing terbinafine in Onychomycosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety and tolerability of topical 10% terbinafine hydrogen chloride applied daily versus 5% amorolfine nail lacquer applied twice a week in patients with mild to moderate toenail onychomycosis, for a total treatment duration of 48 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.
Drug: terbinafine hydrogen chloride
5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.
Drug: amorolfine nail lacquer
10 % terbinafine hydrogen chloride (HCL)
Also known as: Lamisil
5 % amorolfine nail lacquer
Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks
Complete cure is defined as negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.
Time frame: Week 52
Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks.
Complete cure is defined as negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.
Time frame: Week 52
Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Patients for 48 Weeks.
Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and \<= 10% residual involvement of the target toenail.
Time frame: Week 52
Percentage of Participants With Mycological Cure at End of Study After Treating Patients for 48 Weeks
Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes
Time frame: Week 52
Safety and Tolerability Assessed by the Number of Participants With Adverse Events
Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE or SAE and death. Additional details can be found in the Adverse Event Section.
Time frame: Week 52
| Milestone | Terbinafine | Amorolfine |
|---|---|---|
| Started | 507 | 522 |
| Safety population | 493 | 512 |
| Completed | 441 | 446 |
| Not completed | 66 | 76 |
| Withdrew: Adverse event | 1 | 6 |
| Withdrew: Lack of efficacy | 10 | 11 |
| Withdrew: Withdrawal by subject | 20 | 26 |
| Withdrew: Lost to follow-up | 27 | 30 |
| Withdrew: Administrative problems | 3 | 0 |
| Withdrew: Protocol violation | 4 | 3 |
| Withdrew: Missing | 1 | 0 |
Complete cure is defined as negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.
| Percentage of participants | Terbinafine | Amorolfine |
|---|---|---|
| Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks | 1.18 | 0.96 |
Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and \<= 10% residual involvement of the target toenail.
| Percentage of participants | Terbinafine | Amorolfine |
|---|---|---|
| Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Patients for 48 Weeks. | 4.54 | 3.83 |
Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes
| Percentage of participants | Terbinafine | Amorolfine |
|---|---|---|
| Percentage of Participants With Mycological Cure at End of Study After Treating Patients for 48 Weeks | 16.17 | 15.71 |
Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE or SAE and death. Additional details can be found in the Adverse Event Section.
| Participants | Terbinafine | Amorolfine |
|---|---|---|
| At least 1 AE | 285 | 291 |
| AE suspected related to study drug | 11 | 7 |
| At least 1 SAE | 9 | 18 |
| SAE suspected related to study drug | 0 | 0 |
| Death | 0 | 0 |
| Drug discontinuation due to an AE | 1 | 5 |
Complete cure is defined as negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.
| Percentage of participants | Terbinafine | Amorolfine |
|---|---|---|
| Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks. | 1.15 | 0.38 |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Terbinafine | — | 9/493 (1.8%) | 186/493 (37.7%) |
| Amorolfine | — | 18/512 (3.5%) | 168/512 (32.8%) |
| Event | Terbinafine | Amorolfine |
|---|---|---|
| Myocardial infarctionCardiac disorders | 0/493 | 3/512 |
| LymphadenopathyBlood and lymphatic system disorders | 1/493 | 0/512 |
| Enterovesical fistulaGastrointestinal disorders | 1/493 | 0/512 |
| CystitisInfections and infestations | 1/493 | 0/512 |
| DiverticulitisInfections and infestations | 1/493 | 0/512 |
| ErysipelasInfections and infestations | 1/493 | 0/512 |
| PyelonephritisInfections and infestations | 1/493 | 0/512 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/493 | 0/512 |
| Cyst removalSurgical and medical procedures | 1/493 | 0/512 |
| Dupuytren's contracture operationSurgical and medical procedures | 1/493 | 0/512 |
| Event | Terbinafine | Amorolfine |
|---|---|---|
| HeadacheNervous system disorders | 98/493 | 70/512 |
| NasopharyngitisInfections and infestations | 69/493 | 65/512 |
| Tinea pedisInfections and infestations | 29/493 | 33/512 |
| Back painMusculoskeletal and connective tissue disorders | 26/493 | 29/512 |
| InfluenzaInfections and infestations | 25/493 | 15/512 |
| Age, Categorical(Participants) | Terbinafine | Amorolfine | Total |
|---|---|---|---|
| <=18 years | 0 | 1 | 1 |
| Between 18 and 65 years | 425 | 410 | 835 |
| >=65 years | 82 | 111 | 193 |
| Sex: Female, Male(Participants) | Terbinafine | Amorolfine | Total |
|---|---|---|---|
| Female | 158 | 150 | 308 |
| Male | 349 | 372 | 721 |
The record gives a start of Mar 2007, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Terbinafine